Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Blood
|
October 9, 2004
Heparanase promotes the spontaneous metastasis of myeloma cells to bone
Yang Yang, Veronica Macleod, Manali Bendre, et al.
British Journal of Haematology
|
November 9, 2018
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes
Syed J Mehdi, Sarah K Johnson, Joshua Epstein, et al.
Plos One
|
September 26, 2013
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma
Bo Hu, Yu Chen, Saad Z Usmani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
Carolina Schinke, Pingping Qu, Syed J Mehdi, et al.
Haematologica
|
June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
Sarah Waheed, Alan Mitchell, Saad Usmani, et al.
Radiation Research
|
June 4, 2010
Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent
Dan Jia, Nathan A Koonce, Roopa Halakatti, et al.
Haematologica
|
May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood
|
May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
Yang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
February 28, 2017
Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma
Meera Mohan, Rohan S Samant, Donghoon Yoon, et al.
Blood
|
August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Bart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Blood
|
October 9, 2004
Heparanase promotes the spontaneous metastasis of myeloma cells to bone
Yang Yang, Veronica Macleod, Manali Bendre, et al.
British Journal of Haematology
|
November 9, 2018
Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes
Syed J Mehdi, Sarah K Johnson, Joshua Epstein, et al.
Plos One
|
September 26, 2013
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma
Bo Hu, Yu Chen, Saad Z Usmani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
Carolina Schinke, Pingping Qu, Syed J Mehdi, et al.
Haematologica
|
June 27, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data
Sarah Waheed, Alan Mitchell, Saad Usmani, et al.
Radiation Research
|
June 4, 2010
Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent
Dan Jia, Nathan A Koonce, Roopa Halakatti, et al.
Haematologica
|
May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)
Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood
|
May 31, 2007
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
Yang Yang, Veronica MacLeod, Yuemeng Dai, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
February 28, 2017
Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma
Meera Mohan, Rohan S Samant, Donghoon Yoon, et al.
Blood
|
August 2, 2008
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Bart Barlogie, Frits van Rhee, John D Shaughnessy, et al.
Page
of 7